Xalkori Approved For Rare Genetic Form of Lung Cancer 0 11.03.2016 21:34 «La Crosse Tribune» (lacrossetribune.com) FRIDAY, March 11, 2016 (HealthDay News) -- Xalkori (crizotinib) has been approved by the U.S. Food and Drug Administration to treat advanced non-small cell lung cancer (NSCLC) with tumors that have a rare ROS-1 gene mutation. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
